In the United States Court of Federal Claims
                                    OFFICE OF SPECIAL MASTERS
                                          Filed: June 8, 2018

* * * * * * * * * * * * * * * * * * *
DONATA TINA BUSSA,                  *
executor of the estate of           *                                   UNPUBLISHED
ANDREW BUSSA, deceased,             *
                                    *                                   No. 15-202V
                       Petitioner,  *
v.                                  *                                   Special Master Gowen
                                    *
SECRETARY OF HEALTH                 *                                   Petitioner’s Motion for Dismissal;
AND HUMAN SERVICES,                 *                                   Insufficient Proof; Influenza (“Flu”)
                                    *                                   Vaccination; Guillain-Barré
                       Respondent.  *                                   Syndrome (“GBS”); Alternative
* * * * * * * * * * * * * * * * * * *                                   Causes; Severity Requirement.

Ronald C. Homer, Conway, Homer, P.C., Boston, MA, for petitioner.
Adriana R. Teitel, United States Department of Justice, Washington, DC for respondent.

                                    DECISION ON ENTITLEMENT1

        On March 2, 2015, Andrew Bussa (“Mr. Bussa”) filed a claim in the National Vaccine
Injury Compensation Program.2 He alleged that as a result of receiving an influenza (“flu”)
vaccination on October 24, 2013, he developed Guillain-Barré Syndrome (“GBS”), with residual
effects lasting for more than six months. Petition (ECF No. 1); Amended Petition (ECF No. 21).
After Mr. Bussa passed away on February 1, 2016, Ms. Donata Tina Bussa, as executor of his
estate, was substituted as the petitioner. See Order (ECF No. 46).

        On June 6, 2018, petitioner filed a motion for a decision dismissing this claim.
Petitioner’s Motion (ECF No. 68). The motion provides that petitioner has been unable to secure
further evidence required by the Court to prove entitlement to compensation in the Vaccine
Program. Petitioner is aware that a decision by the special master dismissing the petition will
1
  Pursuant to the E-Government Act of 2002, see 44 U.S.C. § 3501 note (2012), because this decision contains a
reasoned explanation for the action in this case, I intend to post it on the website of the United States Court of
Federal Claims. The court’s website is at http://www.uscfc.uscourts.gov/aggregator/sources/7. Before the decision
is posted on the court’s website, each party has 14 days to file a motion requesting redaction “of any information
furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or
confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly
unwarranted invasion of privacy.” Vaccine Rule 18(b). “An objecting party must provide the court with a proposed
redacted version of the decision.” 

party files a motion for redaction within 14 days, the decision
will be posted on the court’s website without any changes. 

Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, 42 U.S.C. §§ 300aa-10 et seq.
(hereinafter “Vaccine Act” or “the Act”). Hereafter, individual section references will be to 42 U.S.C. § 300aa of the
Act.
result in a judgment against petitioner and will end all of petitioner’s rights in the Vaccine
Program. 

to protect her rights to file a civil action in the future.
Therefore, pursuant to 42 U.S.C. § 300aa-21(a)(2), petitioner intends to elect to reject the
Vaccine Program judgment and to file a civil action. 

This matter is now ripe for review.

        Under the Vaccine Act, the Program may not award compensation solely based on a
petitioner’s own claims. Rather, a petitioner must support his claim with either medical records
or the opinion of a competent physician. §13(a)(1). Several challenges to petitioner’s claim
have been apparent over the past three years it has been pending. The first challenge would be to
establish whether Mr. Bussa actually developed GBS, considering that his symptoms had a rapid
onset and then improved without receipt of the usual treatments for GBS, namely, intravenous
immunoglobulin (“IVIG”) and/ or plasma exchange. Mr. Bussa’s symptoms may be alternately
explained by a posterior circulation stroke or a transient ischemic attack (“TIA”). If petitioner
established that Mr. Bussa did have GBS, a further challenge would be to establish that he
experienced the residual effects of GBS for at least six months. This would necessitate
addressing whether Mr. Bussa’s increased fatigue and weakness were more likely related to his
numerous preexisting comorbidities. However, the medical records reflect that Mr. Bussa
complained about dizziness, weakness, and fatigue prior to receiving the vaccination.

       In this case, there is insufficient evidence by way of either medical records or expert
opinion to carry petitioner’s burden of proof. Petitioner’s claim therefore cannot succeed and
must be dismissed. §11(c)(1)(A).

      Thus, this case is dismissed for insufficient proof. The Clerk of the Court shall enter
judgment accordingly.

       IT IS SO ORDERED.
                                                            s/ Thomas L. Gowen
                                                            Thomas L. Gowen
                                                            Special Master




                                                2